Progression Evaluation in Glaucoma (PEG)

  • Research type

    Research Study

  • Full title

    Progression Evaluation in Glaucoma (PEG): Progression of disease in patients newly diagnosed with glaucoma and glaucoma suspects participating in the GATE study

  • IRAS ID

    158131

  • Contact name

    Katie Banister

  • Contact email

    k.banister@abdn.ac.uk

  • Sponsor organisation

    University of Aberdeen

  • Duration of Study in the UK

    0 years, 9 months, days

  • Research summary

    A recently completed diagnostic accuracy study (the GATE study, led by Professor Azuara-Blanco), evaluated whether automated imaging technologies can be used to diagnose glaucoma in hospital services. 966 participants were recruited who had been newly referred for possible glaucoma.

    This research study (PEG) aims to understand more about what happens to patients vision after their referral from the community as they are monitored or treated in hospital eye services. Specifically we will find out how many patients with glaucoma progress to a more severe stage of glaucoma in spite of treatment, and how quickly they progress. We will also find out what happens to patients who are suspected of having glaucoma (glaucoma suspects), and those diagnosed with high eye pressure which puts them at risk of developing glaucoma, and will explore how to better predict who will develop the disease.

    We have some information about how glaucoma progresses from well designed research studies using settings that are not representative of standard care. Unfortunately we do not have good data about what happens to glaucoma patients in real life, under regular NHS care.

    We will review the hospital notes of a sub-set of patients who were included in the GATE study and were followed up in secondary care for 2-4 years. Over this time, some glaucoma patients will have progressed to a more severe disease stage. Others, originally diagnosed as ‘glaucoma suspect’ or with high eye pressure will have clear signs of glaucoma. We will collect information about participants vision to see how often this happens for newly diagnosed patients and how quickly. We will investigate whether any of the characteristics of the person (e.g. age, gender, intraocular pressure, measurements of the retina and optic disc taken at baseline from the GATE study) can predict which patients will have progressive disease.

  • REC name

    North West - Greater Manchester East Research Ethics Committee

  • REC reference

    15/NW/0781

  • Date of REC Opinion

    28 Sep 2015

  • REC opinion

    Favourable Opinion